Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS‐3150) and sodium–glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies-Reference-Cited by-同舟云学术

Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS‐3150) and sodium–glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies

Published:2022-04-21 Issue:7 Volume:13 Page:1190-1202
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J of Diabetes Invest

Author:

Shikata Kenichi¹^ORCID,Ito Sadayoshi²³,Kashihara Naoki⁴,Nangaku Masaomi⁵,Wada Takashi⁶,Okuda Yasuyuki⁷,Sawanobori Tomoko⁸,Sugimoto Kotaro⁹

Affiliation:

1. Center for Innovative Clinical Medicine Okayama University Hospital Okayama Japan

2. Division of Nephrology, Endocrinology and Vascular Medicine Department of Medicine Tohoku University School of Medicine Sendai Japan

3. Katta General Hospital Shiroishi Japan

4. Department of Nephrology and Hypertension Kawasaki Medical School Kurashiki Japan

5. Division of Nephrology and Endocrinology Graduate School of Medicine The University of Tokyo Tokyo Japan

6. Department of Nephrology and Laboratory Medicine Kanazawa University Kanazawa Japan

7. Data Intelligence Department Daiichi Sankyo Co., Ltd. Tokyo Japan

8. Clinical Development Department Daiichi Sankyo Co., Ltd. Tokyo Japan

9. Primary Medical Science Department Daiichi Sankyo Co., Ltd. Tokyo Japan

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdi.13778

Reference40 articles.

1. Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan

3. Changes in Quality of Life in Older Hemodialysis Patients: A Cohort Study on Dialysis Outcomes and Practice Patterns

4. Low health-related quality of life is associated with all-cause mortality in patients with diabetes on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study

5. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Renal effects and safety between Asian and non‐Asian chronic kidney disease and type 2 diabetes treated with nonsteroidal mineralocorticoid antagonists;Journal of Diabetes;2024-05-16

2. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Left Ventricular Hypertrophy (ESES-LVH) Study: A Multicenter, Open-Label, Prospective, Interventional Study;Advances in Therapy;2024-02-04

3. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetes Mellitus Undergoing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors (EAGLE-DH);Advances in Therapy;2023-09-21

4. Renal Protection and Safety of Sodium-glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease;Current Pharmaceutical Design;2023-06

5. Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD;Clinical Journal of the American Society of Nephrology;2023-05-31